This series on “Hepatocellular Carcinoma” is edited by Mehmet Akce, MD, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA; and Shishir K. Maithel, MD, FACS, Winship Cancer Institute, Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, GA, USA.

In this special series, international experts provide an in-depth review of all the aforementioned topics. Despite nearly a decade of negative studies after approval of sorafenib, several new systemic therapy options have emerged in advanced HCC. The clinical trials which led to approval of several recently approved targeted therapy and immunotherapy agents are summarized. Potential systemic therapy options on the horizon and ongoing critical clinical trials are eloquently reviewed here.

Disclosure:
The series “Hepatocellular Carcinoma” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Shishir K. Maithel and Mehmet Akce served as the unpaid Guest Editors for the series.